Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

I'm also curious about BK's thoughts on this matter. In the meantime here are a couple of Leo's comments on the matter. The first comment is excerpted from CTIX PR dated 09/09/13:

"We intend to quickly advance Brilacidin into a Phase 2b clinical trial, a drug that we believe could one day compete with drugs like Pfizer's Zyvox, which generated $1.35 billion in sales in 2012."

Here's the link for this PR;

http://finance.yahoo.com/news/cellceutix-acquires-polymedix-assets-bankruptcy-103000188.html

In a 01/21/14 PR Leo made the following comments:

"Following a week of meeting with other biotechnology companies, investment bankers and analysts, the Company realized that it was significantly undervaluing its estimation of the potential value of Brilacidin for ABSSSI. Several factors influenced the determination, including the dire need for new antibiotics that have not yet developed resistance and are less likely to develop resistance, recent changes in reimbursement policies and an ongoing shift to encourage cost-effective therapies, which is supportive of single-dose treatments, such as two of the dosing regimens in the upcoming Phase 2b trial of Brilacidin. The Company sees reduced reimbursement for the other competing drugs for ABSSSI that have already developed resistance and a higher reimbursement for a drug like Brilacidin, which is needed for patients who have resistance to existing antibiotics. Further, reimbursement is expected to be higher for drugs that prevent serious illness or death and for those where there is no alternative treatment."

Here's the link for this PR:

http://finance.yahoo.com/news/cellceutix-sees-increased-valuation-potential-120000077.html

Looks like the pricing scheme for Brilacidin (presuming it's superior to Dapto) could vary depending on the circumstance of utilization. Like, yourself , I, too, would like to see what BK's educated thoughts are on this subject.